About GenoME Diagnostics

Blood tests have often struggled to make it to patient use. They can be expensive, only relevant to a small subset of patients, lack accuracy, or only detect disease when it is already too late.

GenoME’s mission is to develop novel blood tests for early disease detection and unmet need. We take diagnostics the full way, from innovative biomarker identification directly from blood (or tissue), through to a final multiplexed digital PCR assay.

We focus on novel DNA methylation biomarkers released by cancer cells into the blood stream, combined with novel fragmentomic features. Our tests are drug agnostic, highlight sensitive and specific, and are primed for early detection of extremely low levels of cancer signals in blood samples. We do not require the years and expense into mechanism of action biology.

Our final diagnostic tests are analysed by droplet digital PCR, to ensure sensitive, rapid, high throughput and cost-effective results.

Our pipeline utilises cutting-edge technology, machine learning, and deep optimisation and analytical know-how to provide user-friendly and cost-effective diagnostics. It can be applied to biomarker discovery and development in a wide range of diseases and applications.

Our lead product is OvaME™ for improved ovarian cancer disease monitoring and earlier recurrence detection. Our second product is PanME™ for early detection of pancreatic cancer. We have further tests in development, and are open to partnerships and co-development collaborations.

GenoME Diagnostics Ltd is a spin-out of Queen’s University Belfast founded on a decade of scientific research at the prestigious Johnston Centre for Cancer Research.

Meet our team